Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

NCT06771960 | Recruiting

• 1 other identifier: RVT-LUNG
• Study Type: observational
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.

Conditions

Lung Cancer (NSCLC)

Keywords

lung cancer; Neoadjuvant targeted therapy; residual viable tumor; prognosis; EGFR-Mutated

Outcome Measures

Primary Outcomes (2)

• Disease-free survival (DFS)

  Disease-free survival (DFS) was defined as the time from the date of surgery to the date of recurrence or last follow-up.

  Disease-free survival (DFS) was defined as the time from the date of surgery to the date of recurrence or last follow-up. Estimated final follow-up is 3 years postoperatively.

• Event-free survival (EFS)

  Event-free survival (EFS) was defined as the time from the date of diagnosis to the date of first event (relapse or death) or last follow-up.

  Event-free survival (EFS) was defined as the time from the date of diagnosis to the date of first event (relapse or death) or last follow-up. Estimated final follow-up is 3 years postoperatively.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with EGFR-mutant NSCLC who received neoadjuvant targeted therapy followed by definitive surgery.

You may qualify if:

• Age 18-80 years old;
• Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
• Treated with neoadjuvant targeted therapy;
• Undergoing definitive surgery.

You may not qualify if:

• A history of prior chemotherapy, immunotherapy, or radiotherapy.
• A history of malignancy or lung surgery;
• Missing key data.

Sponsors & Collaborators

• Guangdong Provincial People's Hospital: lead

Study Sites (1)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, 510080, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms

Study Officials

• Guibin Qiao

  Guangdong Provincial People's Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Guibin Qiao

CONTACT

+86-13602749153; guibinqiao@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prof.

Study Record Dates

• First Submitted: January 8, 2025
• First Posted: January 13, 2025
• Study Start: February 1, 2025
• Primary Completion: December 1, 2025
• Study Completion: December 30, 2025
• Last Updated: February 21, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)